sanofi-aventis' AVE5026 meets primary endpoint

sanofi-aventis (Euronext:SAN; SNY) said AVE5026 met the primary endpoint of a reduced risk of venous thromboembolic events compared with Lovenox enoxaparin in the Phase IIb TREK trial in patients requ...